<DOC>
	<DOC>NCT00092027</DOC>
	<brief_summary>This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Women with postmenopausal osteoporosis High risk for fractures Esophageal abnormalities Upper gastrointestinal symptoms that are not relieved with medication Metabolic bone disease (example vitamin D deficiency) Medications that would affect the breakdown or buildup of bone</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>